NovaBridge’s Visara Grants Exclusive License for VIS-101 to Everest Medicines in Asian Market Expansion
October 30, 2025 — 07:00 CST
This Data Is Locked!
This area is available only to Subscribers.
NovaBridge's subsidiary, Visara, has struck a deal with Everest Medicines to license VIS-101, a novel bifunctional biologic for wet AMD, DME, and RVO in Greater... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
